Copied
 
 
Formål
HistorikStartStop
Selskabets formål er at drive virksomhed inden for forskning og udvikling af lægemidler og anden i forbindelse med hermed stående virksomhed17.10.201414.04.2023
Virksomheden har ikke ændret Formål i sin levetid.
Ingen nuværende registrering.
Status
HistorikStartStop
OPLØST EFTER FRIVILLIG LIKVIDATION14.04.202314.04.2023
UNDER FRIVILLIG LIKVIDATION10.10.201613.04.2023
NORMAL18.09.200809.10.2016
Ingen nuværende registrering.
Branche
HistorikStartStop
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)01.01.201314.04.2023
Fremstilling af farmaceutiske præparater (212000)18.09.200831.12.2012
Ingen nuværende registrering.
Revision
HistorikStartStop
false18.09.200814.04.2023
Virksomheden har ikke ændret Revision i sin levetid.
Ingen nuværende registrering.
Revisor
HistorikStartStop
ERNST & YOUNG DENMARK P/S08.01.201314.04.2023
EY Danmark A/S22.05.201208.01.2013
Pryds Statsautoriseret Revisionsfirma18.09.200822.05.2012
Ingen nuværende registrering.
Form
HistorikStartStop
8018.09.200814.04.2023
Virksomheden har ikke ændret Form i sin levetid.
Ingen nuværende registrering.
Kontakt
HistorikStartStop
l.hansen@pkf.dk10.02.201418.09.2014
Virksomheden har ikke ændret Kontakt i sin levetid.
Ingen nuværende registrering.
Telefon
HistorikStartStop
4396065610.02.201418.09.2014
Virksomheden har ikke ændret Telefon i sin levetid.
Ingen nuværende registrering.
Navne
Ingen nuværende registrering.
Tegningsregel
HistorikStartStop
Virksomheden tegnes af en likvidator10.10.201614.04.2023
Selskabet tegnes af den samlede bestyrelse, af en direktør i forening med bestyrelsesformanden, eller af en direktør i foreningen med to bestyrelsesmedlemmer17.10.201409.10.2016
Ingen nuværende registrering.
Ansatte
25.08.2024
Kapital
25.08.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and additionalrequirements applicable in Denmark. Our responsibilities under those standards and requirements arefurther described in the "Auditor's responsibilities for the audit of the financial statements" section of ourreport. We believe that the audit evidence we have obtained is sufficient and appropriate to provide abasis for our opinion. IndependenceWe are independent of the Company in accordance with the International Ethics Standards Board forAccountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirementsapplicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with theserules and requirements.
Konklusion (revision):OpinionWe have audited the financial statements of EpiTherapeutics ApS under frivillig likvidation for thefinancial year 1 January – 31 December 2021, which comprise an income statement, balance sheet,statement of changes in equity and notes, including accounting policies. The financial statements areprepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Companyat 31 December 2021 and of the results of the Company's operations for the financial year 1 January –31 December 2021 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the Liquidator's reviewLiquidator is responsible for Liquidator's review. Our opinion on the financial statements døs not cover the Liquidator's review, and we do not express anyform of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Liquidator’sreview and, in doing so, consider whether the Liquidator 's review is materially inconsistent with thefinancial statements or our knowledge obtained during the audit, or otherwise appears to be materiallymisstated. Moreover, it is our responsibility to consider whether the Liquidator's review provides the informationrequired under the Danish Financial Statements Act. Based on our procedures, we conclude that Liquidator's review is in accordance with the financialstatements and has been prepared in accordance with the requirements of the Danish FinancialStatements Act. We did not identify any material misstatement of the Liquidator's review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
25.08.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
25.08.2024
Ingen nuværende registrering.
Ingen historik.